Event Details

Verastem Inc at 12th International Mesothelioma Interest Group (iMig) Conference

Oct 22, 2014 at 12:00 PM EDT to Oct 24, 2014 at 11:59 PM EDT
Title
Verastem Inc at 12th International Mesothelioma Interest Group (iMig) Conference
Date / Time
Oct 22, 2014 at 12:00 PM EDT to Oct 24, 2014 at 11:59 PM EDT

iMig Special Keynote Lecture: “Cancer Stem Cells as Target Pathways”
Presenter: Robert Weinberg, Ph.D., Whitehead Institute and Verastem scientific cofounder and chair of the Scientific Advisory Board

Presentation Title: “Determination of Biomarker response in a Phase II Window of Opportunity Study of Defactinib (VS-6063), a Focal Adhesion Kinase (FAK) Inhibitor, in Subjects with Resectable MPM”
Presenter: Raphael Bueno, M.D., Chief, Division of Thoracic Surgery, Brigham & Women’s Hospital, Boston, MA

Presentation Title: “FAK Inhibitor VS-6063 (Defactinib) Targets Mesothelioma Cancer Stem Cells which are Enriched by Standard of Care Chemotherapy”
Presenter: Paul Baas, M.D., Ph. D., Department of Thoracic Oncology,The Netherlands Cancer Institute

Presentation Title: “The Cancer Stem Cell Inhibitors VS-6063 (Defactinib) and VS-5584 Exhibit Synergistic Anticancer Activity in Preclinical Models of Mesothelioma”
Presenter: Mitchell Keegan, Ph.D., Vice President, Development, Verastem

Investor Contact

getty
John Doyle

VP Investor Relations & Finance
781.292.4279
jdoyle@verastem.com

Joe Rayne

Argot Partners
617.340.6075
joseph@argotpartners.com